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background:  Transcatheter implantation of aortic valves (TAVR) has revolutionized management of severe aortic stenosis. Specific 
complications have been seen with 1st generation valves. Details of such were sought from the US Food and Drug Administration (FDA) 
MAUDE database which houses medical device reports submitted by mandatory and voluntary reporters.
methods:  A detailed search was conducted in PubMed, Cochrane Library, EMBASE and CINAHL to identify adverse events reported with 
implantation of the 1st generation Edwards-Sapien (ES) valves. Then the FDA MAUDE database was queried from 2011 to July 31, 2014 
to identify prevalence of the same complications. Individual patient data on such complications were abstracted. Finally mortality outcomes 
were abstracted, and associations of same for each individual reported complication were identified in a multivariate logistic regression 
model.
results:  FDA MAUDE revealed 1438 unique reports of complications with the 1st generation ES valves. A total of 303 patients died peri-
procedurally. The complications most strongly associated with peri-procedural mortality were development of peri-procedural cardiogenic 
shock, significant bleeding, development of mitral regurgitation, valve migration post placement, and development of acute renal failure.
Conclusion:  There was a strong association between specific complications and mortality. Focused strategies to mitigate these may 
improve outcomes in future.
Death Odds Ratio Std. Err. Z P>z 95% CI(L) 95% CI (H)
Cardiogenic Shock 1.905569 0.532425 2.31 0.021 1.102033 3.294993
Need for IABP 0.852742 0.243595 -0.56 0.577 0.48715 1.492701
Annulus rupture 1.757708 0.761668 1.3 0.193 0.751788 4.109586
Aortic Root Surgery 11.1043 15.8886 1.68 0.092 0.672277 183.4147
Pericardiocentesis 0.425892 0.169813 -2.14 0.032 0.194942 0.930451
Vascular Complications 3.416703 0.689777 6.09 0.001 2.300189 5.075174
Bleeding 2.577692 0.684139 3.57 0.001 1.532202 4.336569
Myocardial Injury 1.657545 0.729296 1.15 0.251 0.69976 3.926283
Heart Block 0.457749 0.261768 -1.37 0.172 0.149231 1.404089
Need for PPM 0.365568 0.174303 -2.11 0.035 0.143587 0.930723
Atrial Fibrillation 0.915118 0.475244 -0.17 0.864 0.330694 2.532375
Central Aortic Insufficiency (AI) 0.925806 0.192695 -0.37 0.711 0.615676 1.392154
Paravalvular AI 0.576723 0.11863 -2.68 0.007 0.385371 0.86309
CVA/Stroke 1.748 0.520919 1.87 0.061 0.974712 3.134777
Valve Malposition 0.982568 0.216543 -0.08 0.936 0.637927 1.513401
Valve in valve 0.238968 0.057955 -5.9 0 0.148561 0.384391
Mitral Valve injury 9.831881 10.30599 2.18 0.029 1.260053 76.71575
Valve Migration 2.131376 0.636231 2.54 0.011 1.187327 3.826043
Renal Failure 10.61745 5.336276 4.7 <0.001 3.964706 28.43346
